COVID-19 Related – Natural and Semi-Synthetic Saponins as Vaccine Adjuvants

This technology and its patent applications describe the chemical synthesis and vaccine applications of structurally defined and homogenous analogs of the natural saponin adjuvants, including those isolated from the tree bark of Quillaja saponaria Molina (particularly analogs of QS-7, QS-17, QS-18, and QS-21). When administered as adjuvants in mouse immunization studies, these saponin analogs elicit equal to greater IgG responses than GPI-0100. The low cost and time required for synthesis makes these adjuvants an attractive alternative to conventional adjuvants currently on the market. C Scott Swindle (205) 996-7578

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More